期刊文献+

血清CA15-3、CA125联合MMP-1和IL-10检测在乳腺癌诊断和预后评估中的价值探讨 被引量:14

The Value of Serum CA15-3,CA125 Combined with MMP-1 and IL-10 in the Diagnosis and Prognosis Evaluation of Breast Cancer
下载PDF
导出
摘要 目的探究血清CA15-3、CA125联合基质金属蛋白酶-1(MMP-1)和白细胞介素-10(IL-10)水平在乳腺癌(BC)诊断和预后评估中的临床价值。方法收集2014年1月至2016年1月期间入我院就诊的BC患者104例,同期选取健康体检者80例。采用t检验分析血清CA15-3、CA125、MMP-1和IL-10在组间的差异,运用受试者工作特征曲线(ROC)技术分析血清CA15-3、CA125、MMP-1和IL-10在鉴别诊断BC的临床价值。相关性分析采用Spearman检验。多项Logistic回归分析计算(OR)及其95%置信区间(CI)。采用Kaplan-Meier法和对数秩检验(log-rank test)进行生存分析。结果与健康组相比,BC患者血清CA15-3、CA125、MMP-1和IL-10水平均显著增高(P均<0.05)。ROC曲线分析显示,当联合血清CA15-3、CA125、MMP-1和IL-10在区分BC与健康对照组时的灵敏度和特异性均明显提升,分别为91.5%和93.0%。多元Logistic回归多因素分析显示,在校正年龄、吸烟、饮酒、糖尿病和CA125等因素影响后,高MMP-1、高IL-10和高BMI是BC的独立危险因素。生存分析显示,高MMP-1组患者的生存时间显著低于低MMP-1组患者(log-rank P=0.035),而血清高IL-10与低IL-10组间的生存时间差异无统计学意义(log-rank P=0.475)。结论血清MMP-1和IL-10联合CA15-3和CA125在BC诊断中以及血清MMP-1在评估BC患者预后中均具有重要临床意义。 Objective To explore the clinical value of serum CA15-3, CA125 combined with matrix metalloproteinase-1 (MMP-1)and interleukin -10 (IL-10)level in diagnosis and prognosis evaluation of breast cancer(BC). Methods A total of 104 BC patients were enrolled in our hospital from January 2014 to January 2016, and 80 healthy cases were selected at the same time. The differences of serum CA15-3, CA125, MMP-1 and IL-10 between groups were analyzed by t test. The clinical value of serum CA15-3,CA125, MMP- 1 and IL- 10 in the differential diagnosis of BC was analyzed by receiver operating characteristic curve (ROC). Spearman test was used for the correlation analysis. Multiple logistic regression was used to analyses the ORs and its 95% confidence intervals (CIs). The Kaplan -Meier method and the logarithmic rank test (log-rank test)were used for survival analysis. Results Compared with the health group, the levels of CA15-3 ,CA125 ,MMP-1 and IL-10 in the serum of BC patients were significantly higher( P 〈 0.05 ). ROC curve analysis showed that the sensitivity and specificity of combined serum CA15-3, CA125 ,MMP-1 and IL- l0 in differentiating BC and healthy controls significantly increased, which were 91. 5% and 93% respectively. Multivariate logistic regression analysis showed that high MMP-1, high IL-10 and high BMI were independent risk factors of BC after adjusting for age, smoking, drinking, diabetes and CA125. Survival analysis showed that the survival time of patients in high MMP-1 group was significantly lower than that in low MMP- 1 group ( log- rank P = 0. 035 ), but there was no significant difference in the survival time betweenhigh serum IL-10 and low IL-10 group (log-rank P = 0. 475 ). Conclusion The diagnostic value of serum MMP-1 and IL-10 combined with CA15-3 and CA125 in BC and the important clinical significance of serum MMP-1 in evaluating the prognosis of BC patients.
作者 杨文国 YANG Wen-guo(General Surgery,Affiliated Hospital of Inner Mongolia University for Nationalities,Hohhot 028000,China)
出处 《标记免疫分析与临床》 CAS 2018年第8期1107-1113,共7页 Labeled Immunoassays and Clinical Medicine
关键词 基质金属蛋白酶-1 白细胞介素-10 乳腺癌 临床价值 MMP- 1 IL- 10 Breast cancer Clinical value
  • 相关文献

参考文献8

二级参考文献78

  • 1张思维,雷正龙,李光琳,邹小农,陈万青,赵平.中国肿瘤登记地区2005年发病死亡资料分析[J].中国肿瘤,2009,18(12):973-979. 被引量:32
  • 2王启俊,祝伟星,邢秀梅.北京城区女性乳腺癌发病死亡和生存情况20年监测分析[J].中华肿瘤杂志,2006,28(3):208-210. 被引量:81
  • 3全国肿瘤防治研究办公室.中国恶性肿瘤死亡调查研究(1990-1992)[M].北京:人民卫生出版社,2008.82-101.
  • 4Samy N’Ragab HM,E1 Maksoud NA,et al. Prognostic sig-nificance of serum Her2 /neu, BCL2, CA15-3 and CEA inbreast cancer patients : a short follow-up [ J ]. Cancer Bio-mark,2010,6(2) :63-72.
  • 5Sandri MT,Salvatici M,Botteri E, et al. Prognostic role ofCA15-3 in 7942 patients with operable breast cancer [ J ].Breast Cancer Res Treat,2012,132( 1 ) :317-326.
  • 6Fersching DM,Nagel D,Siegele B,et al. Apoptosis-relatedbiomarkers sFAS, MIF, ICAM-1 and PAI-1 in serum ofbreast cancer patients undergoing neoadjuvant chemotherapy[J]. Anticancer Res,2012,32(5) :2047-2058.
  • 7Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
  • 8De Santis C,Ma J,Bryan L,et al.Breast cancer statistics,2013[J].CA Cancer J Clin,2014,64(1):52-62.
  • 9De Santis C,Siegel R,Bandi P,et al.Breast cancer statistics,2011[J].CA Cancer J Clin,2011,61(6):409-418.
  • 10Mettlin C.Global breast cancer mortality statistics[J].CA Cancer J Clin,1999,49(3):138-144.

共引文献1347

同被引文献155

引证文献14

二级引证文献75

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部